acquires HRT brands from Mercury Pharma. Dr Reddy's Labs acquired trademarks Progynova and CycloProgynova, and related assets in India from Mercury Pharma Group Ltd for $32.15 million. These specialty brands provide hormone replacement therapy and gynaecology treatments, reinforcing Dr Reddy's gynaecology portfolio in India. Progynova recorded ₹100 crore sales in 2025 and is the No. 1 brand in India's estradiol represented market. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.